• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

EMA validates Gilead’s Type II variation application for Truvada for PrEP

1 February 2016  •  Author: Victoria White

Gilead’s Type II variation application for once-daily Truvada (emtricitabine 200mg/tenofovir disoproxil fumarate 300mg) in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 infection among uninfected adults at high risk, a strategy known as pre-exposure prophylaxis or PrEP, has been fully validated and is now under evaluation by the European Medicines Agency (EMA). 

Truvada for PrEP

Truvada was approved by the EMA in 2005 in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults, and is currently the most prescribed antiretroviral treatment in Europe.

Professor Sheena McCormack, Medical Research Council Clinical Trials Unit, University College London, said: “We are excited by the potential public health impact Truvada for PrEP may have, as part of a comprehensive HIV prevention strategy, in lowering transmission rates among at-risk populations across Europe.”

Applicatoin based on iPrEX and Partners PrEP trials

The application is based on the results of two large placebo-controlled trials of Truvada for PrEP, the Pre-Exposure Prophylaxis Initiative (iPrEX) and Partners PrEP. The indication extension will be reviewed by the EMA under the centralised procedure, which, when finalized, may lead to the granting of marketing authorisation by the European Commission, which is valid in all 28 member states of the European Union (EU).

In all studies of Truvada for PrEP, the most commonly reported side effects included headache, stomach discomfort and weight loss.  The incidence and types of side effects were consistent with Truvada’s safety and tolerability profile when used as an HIV treatment.

“The EMA filing for Truvada for PrEP is timely given the growing body of evidence supporting its use in preventing HIV and the interest expressed by the medical and patient advocacy communities,” said Norbert W. Bischofberger, PhD, Gilead’s Executive Vice President, Research and Development and Chief Scientific Officer.  “Appropriate use of Truvada for PrEP is supported by European AIDS Clinical Society and World Health Organization guidelines, and Gilead believes it is an important HIV prevention tool that, when taken as directed and used in combination with other prevention strategies, has the potential to help reduce new HIV infections.”

Truvada was approved for PrEP in the United States in 2012, and in Kenya and South Africa in 2015; regulatory submissions are pending in Australia, Brazil, Canada, Peru and Thailand.  Additionally, within the EU, Truvada for PrEP is currently available in France following a Temporary Recommendation for Use by the French regulatory agency (ANSM).

Leave a reply

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +